About Ilico Genetics
Ilico Genetics is a company based in Bethlehem (United States) founded in 2020 by Fernando Alarcon Hardy, Alejandro Corvalan, and Maria Maturana. Ilico Genetics has raised $457.74 thousand across 1 funding round. Ilico Genetics offers products and services including Stomach Cancer Screening Test. Ilico Genetics operates in a competitive market with competitors including Intima Bioscience, Draconis Pharma, Shgsmed.com, Checkmate Therapeutics and TLR Therapeutics, among others.
- Headquarter Bethlehem, United States
- Founders Fernando Alarcon Hardy, Alejandro Corvalan, Maria Maturana
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$457.74 K (USD)
in 1 rounds
-
Latest Funding Round
$457.74 K (USD), Seed
Oct 27, 2023
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ilico Genetics
Ilico Genetics offers a comprehensive portfolio of products and services, including Stomach Cancer Screening Test.
Blood test to detect early-stage gastric cancer before symptoms.
People of Ilico Genetics
Unlock access to complete
Unlock access to complete
Funding Insights of Ilico Genetics
Ilico Genetics has successfully raised a total of $457.74K through 1 strategic funding round. The most recent funding activity was a Seed round of $457.74 thousand completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Ilico Genetics
Investment portfolio details for Ilico Genetics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ilico Genetics
Detailed financials for Ilico Genetics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ilico Genetics Comparisons
Peer comparison for Ilico Genetics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ilico Genetics
Ilico Genetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Intima Bioscience, Draconis Pharma, Shgsmed.com, Checkmate Therapeutics and TLR Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal cancer are developed using CRISPR gene-editing.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for cancer, pain, and immune diseases are developed.
|
|
| Locked | Locked | Locked |
Drugs for esophageal cancer treatment are developed using photodynamic therapy.
|
|
| Locked | Locked | Locked |
Develops innovative therapeutic technologies for cancer and neurological disorders.
|
|
| Locked | Locked | Locked |
Develops innovative therapeutics for treating myelodysplastic syndrome and gastric cancer.
|
Detailed competitors of Ilico Genetics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ilico Genetics
Complete news archive for Ilico Genetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ilico Genetics
Ilico Genetics was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Ilico Genetics is headquartered in Bethlehem, United States.
Fernando Alarcon Hardy is the current CEO of Ilico Genetics. They have also founded this company.
Ilico Genetics is a funded company, having raised a total of $457.74K across 1 funding round to date.
Ilico Genetics was founded in 2020 in Bethlehem, United States, within the biotechnology sector. Diagnostic tests for gastric cancer are developed, focusing on molecular analysis of methylated DNA obtained from blood samples. Tumors or lesions in the stomach are detected through this non-invasive method. Operations center on advancing early detection technologies for oncology applications in the diagnostic industry.
Ilico Genetics's top competitors include Draconis Pharma, Intima Bioscience and Shgsmed.com.
Ilico Genetics offers Stomach Cancer Screening Test.